---
schema_version: "secwatch.filing_event.v1"
accession: "0001528287-21-000009"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T12:53:39.745885+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeuroPace Q2 revenue $12.6M (+65% YoY); initial implants up 100%; reaffirms FY guidance

## Summary
- Total revenue $12.6M (+65% YoY); initial implant revenue $9.2M (+100% YoY, +14% QoQ).
- Net loss $8.5M vs $8.8M; cash $127.9M; long-term debt $49.4M.
- Reaffirmed FY2021 guidance: total revenue ~$47M, initial implant ~$36M.
- Received up to $9.3M NIH BRAIN grant to evaluate RNS System for Lennox-Gastaut Syndrome.
- Plans to start enrolling adolescent epilepsy patients before year-end; IDE for primary generalized epilepsy in 2021.

## SEC filing metadata
- accession: 0001528287-21-000009
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000152828721000009/0001528287-21-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000152828721000009/npce-20210812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001528287-21-000009
- JSON: https://secwatch.observer/filing/0001528287-21-000009.json
- Plain text: https://secwatch.observer/filing/0001528287-21-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.